Drugs / CUDC-305
CUDC-305
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03675542 | Nov 2018 → Nov 2019 | psoriasis | Aarhus University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01714037 | Aug 2012 → Nov 2014 | non-small cell lung carcinoma | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT01168752 | Apr 2010 → Apr 2013 | cancer, lymphoma | Debiopharm International SA | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUDC-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03675542 ↗ |
| Known as | Cudc305 (hsp90 inhibitor) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2419346 ↗ |
| Known as | Debio0932 | “BACKGROUND: Objective was to determine maximum tolerated dose (MTD), recommended dose (RD) and schedule, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) effects, and...” PMID 25646368 ↗ Feb 2015 |
| Known as | Hsp90 inhibitor debio 0932 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2419346 ↗ |
| Action | Inhibit | “Debio0932, a new second-generation oral heat shock protein (HSP) inhibitor.” PMID 25646368 ↗ Feb 2015 |
| Modality | Small molecule | “Oral HSP90 Inhibitor Debio 0932” NCT01714037 ↗ |
| Route | Oral | “Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.” NCT01168752 ↗ |